Ammerman, Nicole C, Nuermberger, Eric L, Owen, Andrew 
ORCID: 0000-0002-9819-7651, Rannard, Steve P ORCID: 0000-0002-6946-1097, Meyers, Caren Freel and Swindells, Susan
(2022)
Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment.
CLINICAL INFECTIOUS DISEASES, 75 (Suppl ).
S510-S516.
Abstract
A key component of global tuberculosis (TB) control is the treatment of latent TB infection. The use of long-acting technologies to administer TB preventive treatment has the potential to significantly improve the delivery and impact of this important public health intervention. For example, an ideal long-acting treatment could consist of a single dose that could be administered in the clinic (ie, a "1-shot cure" for latent TB). Interest in long-acting formulations for TB preventive therapy has gained considerable traction in recent years. This article presents an overview of the specific considerations and current preclinical advancements relevant for the development of long-acting technologies of TB drugs for treatment of latent infection, including attributes of target product profiles, suitability of drugs for long-acting formulations, ongoing research efforts, and translation to clinical studies.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | latent tuberculosis infection, long-acting, tuberculosis, tuberculosis preventive treatment |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology Faculty of Science and Engineering > School of Physical Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 29 Sep 2023 15:53 |
| Last Modified: | 29 Sep 2023 15:55 |
| DOI: | 10.1093/cid/ciac672 |
| Open Access URL: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200... |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3172014 |
Dimensions
Dimensions
